References
- 1. Chaker L., Razvi S., Bensenor I. et al. (2022) Hypothyroidism. Nat. Rev. Dis. Primers, 8(30). doi.org/10.1038/s41572-022-00357-7.
- 2. Mooij C., Cheetham T., Verburg F. et al. (2022) European Thyroid Association Guideline for the management of pediatric Graves’ disease. Eur. Thyroid. J., 11(1): e210073.
- 3. Paschou S., Bletsa E., Stampouloglou P. et al. (2022) Thyroid disorders and cardiovascular manifestations: an update. Endocrine, 75(3): 672–683. doi: 10.1007/s12020-022-02982-4.
- 4. Stojković M., Žarković M. (2020) Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease. Cur. Pharmaceut. Design, 26(43): 5617–5627. doi.org/10.2174/1381612826666201118094747.
- 5. Peppa M., Betsi G., Dimitriadis G. (2011) Lipid Abnormalities and Cardiometabolic Risk in Patients with Overt and Subclinical Thyroid Disease. J. Lipids, 2011: 575840. doi: 10.1155/2011/575840.
- 6. Selmer C., Olesen J.B., Hansen M.L. et al. (2014) Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J. Clin. Endocrinol. Metab., 99(7): 2372–2382. doi: 10.1210/jc.2013-4184.
- 7. Mastorci F., Sabatino L., Vassalle C., Pingitore A. (2020) Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure. Front. Endocrinol. (Lausanne), 10: 927. doi: 10.3389/fendo.2019.00927.
- 8. Liu Y.Y., Brent G.A. (2010) Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol. Metab., 21(3): 166–173. dx.doi.org/10.1016/j.tem.2009.11.004.
- 9. Gluvic Z.M., Obradovic M.M., Sudar-Milovanovic E.M. et al. (2020) Regulation of nitric oxide production in hypothyroidism. Biomed. Pharmacother., 124: 109881. doi: 10.1016/j.biopha.2020.109881.
- 10. Guzmán-Gutiérrez E., Veas C., Leiva A. et al. (2014) Is a low level of free thyroxine in the maternal circulation associated with altered endothelial function in gestational diabetes? Front. Pharmacol., 5: 136. doi: 10.3389/fphar.2014.00136.
- 11. Hernando V., Eliana M. (2015) Role of thyroid hormones in different aspects of cardiovascular system. Endocrinol. Metab. Synd., 4(2): 1000166. DOI: 10.4172/2161-1017.1000166.
- 12. Zheng Y.S., Dong S.Y., Gong Y. et al. (2022) Comparison of Five Different Criteria for Diagnosis of Subclinical Hypothyroidism in a Large-Scale Chinese Population. Front. Endocrinol. (Lausanne), 13: 820414. doi: 10.3389/fendo.2022.820414.
- 13. Jonklaas J. (2022) Optimal Thyroid Hormone Replacement. Endocr. Rev., 43(2): 366–404. doi: 10.1210/endrev/bnab031.
- 14. Eom Y.S., Wilson J., Bernet V.J. (2022) Links between thyroid disorders and glucose homeostasis. Diabetes Metab. J., 46(2): 239–256. doi.org/10.4093/dmj.2022.0013.
- 15. Jabbar A., Pingitore A., Pearce S. et al. (2017) Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol., 14(1): 39–55. doi: 10.1038/nrcardio.2016.174.
- 16. Manolis A.A., Manolis T.A., Melita H., Manolis A.S. (2020) Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call? Trends Cardiovasc. Med., 30(2): 57–69. doi: 10.1016/j.tcm.2019.02.011.
- 17. Tohidi M., Derakhshan A., Akbarpour S. et al. (2018) Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study. Horm. Metab. Res. 50(1): 37–43. doi: 10.1055/s-0043-121031.
- 18. Yang G., Wang Y., Ma A., Wang T. (2019) Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. BMC Cardiovasc. Disord., 19(1): 83. doi: 10.1186/s12872-019-1055-x.
- 19. Житникова Л.М. (2012) Метаболическая терапия, или кардиоцитопротекция — как необходимый компонент комбинированной терапии сердечно-сосудистых заболеваний. РМЖ (Русский медицинский журнал), 4: 137–143.
- 20. Возможности метаболической терапии у пациентов с сердечно-сосудистой патологией (2018) Укр. мед. часопис, 2(1) (124): http://www.umj.com.ua/article/123917.
- 21. Longo N., Frigeni M., Pasquali M. (2016) Carnitine transport and fatty acid oxidation. Biochim. Biophys. Acta, 1863(10): 2422–2435. doi: 10.1016/j.bbamcr.2016.01.023 330.
- 22. Virmani M.A., Cirulli M. (2022) The Role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. Intern. J. Molec. Sci., 23(5): 2717. DOI: 10.3390/ijms23052717.
- 23. Vaz F.M., Wanders R.J. (2002) Carnitine biosynthesis in mammals. Biochem. J., 361(Pt 3): 417–429. doi: 10.1042/0264-6021:3610417.
- 24. Benvenga S., Amato A., Calvani M., Trimarchi F. (2004) Effects of carnitine on thyroid hormone action. Ann. N.Y. Acad. Sci., 1033: 158–167. doi: 10.1196/annals.1320.015.
- 25. An J.H., Kim Y.J., Kim K.J. et al. (2016) L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment: a randomized, double-blind, placebo-controlled trial. Endocr. J., 63(10): 885–895.
- 26. Sinclair C., Gilchrist J., Hennessey J., Kandula M. (2005) Muscle carnitine in hypo- and hyperthyroidism. Muscle Nerve, 32: 357–359. doi: 10.1002/mus.20336.
- 27. De Felice S., Gilgore S. (1966) The antagonistic effect of carnitine in hyperthyroidism. Preliminary report. J. N. Drugs, 6: 351–353. doi: 10.1177/009127006600600607.
- 28. Benvenga S., Lakshmanan M., Trimarchi F. (2000) Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid, 12: 1043–1050. doi: 10.1089/thy.2000.10.1043.
- 29. Chee R., Agah R., Vita R., Benvenga S. (2014) Severe hyperthyroidism treated with L-carnitine, propranolol, and finally with thyroidectomy in a seriously ill cancer patient. Hormones, 13: 407–412.
- 30. Nordio M. (2017) A novel treatment for subclinical hyperthyroidism: A pilot study on the beneficial effects of L-carnitine and selenium. Eur. Rev. Med. Pharmacol. Sci., 21: 2268–2273.
- 31. Benvenga S., Ruggeri R., Russo A. et al. (2001) Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: A randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab., 86: 3579–3594. doi: 10.1210/jcem.86.8.7747.
- 32. Wang Z.Y., Liu Y.Y., Liu G.H. et al. (2018) l-Carnitine and heart disease. Life Sci., 194: 88–97. doi: 10.1016/j.lfs.2017.12.015.
- 33. Xue Y.Z., Wang L.X., Liu H.Z. et al. (2007) L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc. Drugs Ther., 21: 445–448. doi: 10.1007/s10557-007-6056-9.
- 34. Singh R.B., Niaz M.A., Agarwal P. et al. (1996) A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad. Med. J., 72: 45–50. doi: 10.1136/pgmj.72.843.45.
- 35. Askarpour M., Hadi A., Symonds M.E., Miraghajani M. (2019) Efficacy of L-carnitine supplementation for management of blood lipids: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrition, metabolism, and cardiovascular diseases, 29(11). DOI: 10.1016/j.numecd.2019.07.012.
- 36. Гонський Я.І., Максимчук Т.П. (2001) Біохімія людини. Укрмедкнига, Тернопіль, 736 с.
- 37. Banjarnahor S., Rodionov R.N., König J., Maas R. (2020) Transport of L-Arginine Related Cardiovascular Risk Markers. J. Clin. Med., 9(12): 3975. doi: 10.3390/jcm9123975.
- 38. Toral M., Jimenez R., Montoro-Molina S. et al. (2018) Thyroid hormones stimulate L-arginine transport in human endothelial cells. J. Endocrinol., 239(1): 49–62. doi.org/10.1530/JOE-18-0229.
- 39. Bronte V., Serafini P., Mazzoni A. et al. (2003) L-аrginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol., 24: 302–306.
- 40. Verma M., Dahiya K., Ghalaut V. et al. (2015) Thyroid disorders and nitric oxide levels. J. Science, 5(1): 4–8.
- 41. Huseyin V., Tamer M., Weiskirchen R. (2021) Evaluation of Arginine-Nitric Oxide Pathway in Patients with Hyperthyroidism. Electronic J. General Med., 18(2): em278. DOI: 10.29333/ejgm/9696.